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 Umbilical cord blood transfusions in low-income countries 
Since 1988, umbilical cord blood has been used as 
a valuable source of haemopoietic stem cells for 
allogeneic transplantation.1 A global network of cord 
blood banks has been established, with a common 
inventory of around 600 000 units cryopreserved and 
stored and about 30 000 units distributed worldwide 
to treat children and adults with severe malignant 
and non-malignant haematological diseases. Because 
of lymphocyte immaturity at birth, HLA mismatches 
between donor and recipient can be tolerated with use 
of umbilical cord blood; therefore, cord blood expands 
the donor pool, including to people from some ethnic 
groups that are under-represented in donor registries. 
The absence of ethical issues surrounding umbilical 
cord blood, and its abundant supply, accounts for the 
increasing interest in use of cord blood for stem-cell 
treatments.
Umbilical cord blood has a rich mix of fetal and adult 
haemoglobin and plasma ﬁ lled with cytokines and 
growth factors, making it a potentially eﬃ  cient and 
safe alternative to conventional blood transfusion 
for management of anaemia in urgent situations. 
Cord blood could be especially beneﬁ cial in countries 
with high rates of morbidity and mortality from 
haemoglobinopathies, a group of diseases in which 
blood enriched with fetal haemoglobin, with its high 
oxygen-carrying capacity, might be superior to adult 
blood. 
The possibility of using of umbilical cord blood as an 
alternative source of red blood cells for transfusion is 
especially important in low-income countries, where 
health resources are limited and blood supply does not 
meet the needs of the population. The prevalence of 
HIV/AIDS, malaria, and other infectious diseases in Africa 
is high, but eﬀ orts are growing to increase access to safe 
and eﬀ ective blood transfusion. Implementation of such 
programmes to meet uniform standards and improve 
quality and safety, with appropriate infrastructure and 
eﬀ ective donor education and recruitment, is costly and 
dependent on political will, support, and commitment 
from health authorities and appropriately trained and 
skilled staﬀ .  
In The Lancet Haematology, Oliver Hassall and 
colleagues describe a prospective clinical trial set in 
Kenya,2 in which red blood cells from umbilical cord 
blood were used for transfusions in children with 
severe anaemia. Cord blood donations were screened 
for transfusion-transmitted infections and bacterial 
contamination. Red blood cells were recovered by 
sedimentation during refrigerated storage. Hassall and 
colleagues monitored adverse events and measured 
haemoglobin levels 24 h and 28 days after transfusion. 
Overall, the concentration of haemoglobin increased 
from pretransfusion levels, by a median of 26 g/L 
(IQR 21–31) 24 h after transfusion, and by 50 g/L 
(10–68) around 28 days after transfusion, with only 
a few severe adverse eﬀ ects recorded, indicating the 
safety and eﬃ  cacy of this innovative approach. 
Use of red blood cells from umbilical cord blood has 
been reported previously.3,4 Furthermore, in a study 
from India, more than 1000 cord blood transfusions 
were done in children and adults for various indications, 
in an apparently safe and eﬃ  cient manner.5 Although 
promising, further work needs to be done to ensure 
criteria for quality of blood transfusions in developed 
countries are fulﬁ lled in developing regions.
Rules for collection and use of cord blood must 
follow standards developed by the Foundation for 
the Accreditation of Cellular Therapy (FACT) and the 
International NetCord Foundation with respect to 
informed consent, criteria for inclusion and exclusion, 
processing, screening of the mother and cord blood 
for infectious diseases, traceability, transportation, and 
recording of adverse events. Criteria for donor inclusion 
and exclusion is a concern in countries of low income, 
where prematurity, malnutrition, low birthweight, and 
anaemia are frequent. Furthermore, prolonged debate 
has taken place regarding the safety and development 
of the donor baby on early versus late clamping of the 
umbilical cord when the blood is collected; ﬁ ndings 
of a randomised study showed that delayed clamping 
did not aﬀ ect iron status or neurodevelopment at age 
12 months in a selected population of healthy infants 
born at term.6 However, this clamping study was done 
in a developed country with good health facilities; 
therefore, validation of ﬁ ndings would be advisable in 
less-developed countries that plan to establish a cord 
blood collection programme. 
Although parasitic and viral contamination of 
cord blood is theoretically diminished because of the 
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mother–placental blood barrier, the same strict exclusion 
criteria for blood donors should be applied to cord blood 
donations, and infectious disease transmission is still 
a concern. In the study by Hassall and colleagues, the 
number of transfusion-related bacterial infections was 
low, not only because of rigorous selection and testing 
of donors but also because ﬁ eldworkers were trained to 
aseptic collection and handling of umbilical cord blood. 
However, maintaining the same strict standards outside 
of the research setting is challenging and demands 
supplementary resources. This procedure is especially 
diﬃ  cult in places with few health-care personnel and a 
high work burden. 
Additional studies are needed before the generalised 
use of cord blood for transfusion can be implemented. 
However, these early results are very promising for 
decreasing morbidity and mortality in Kenya and other 
less-developed countries.
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